RX Biosyent Inc

BioSyent Inc. ("BioSyent")(TSX VENTURE:RX) today announced that its subsidiary
BioSyent Pharma Inc. has commenced the Canadian launch of its unique new oral
iron supplement - FeraMAX(R) Powder.


FeraMAX(R) Powder is the first innovation in the pediatric oral iron market in
Canada in almost 50 years. The Canadian market launch will be the global
introduction of this new product and provides BioSyent Pharma with a unique
offering for international marketing partners.


FeraMAX(R) Powder joins FeraMAX(R) 150 in providing healthcare professionals and
their patients with a safe, effective, and well tolerated oral iron supplement.
It is indicated for the prevention of iron deficiency and iron deficiency
anaemia in newborns, infants, children and adults.


FeraMAX(R) Powder is the only oral iron product available in a dissolvable
powder and comes in pleasant tasting grape/raspberry flavoured gluten and
alcohol-free crystals which can be conveniently dosed by diluting in water or
mixing with soft foods. This innovative new product is based upon the same
doctor recommended, proprietary, non-ionic polysaccharide-iron complex
technology found in FeraMAX(R) 150. 


Other oral iron products intended for infants and children either have an
unpleasant heavy metallic taste which deter patient compliance or they come in
formulations containing alcohol which healthcare professionals and caregivers
prefer to avoid. In addition to its clear advantages in the pediatric market,
FeraMAX(R) Powder is also well suited for adult patients that have difficulty
swallowing pills.


FeraMAX(R) Powder was exhibited at the recent Primary Care Today medical
conference attended by over 3,000 healthcare professionals. Listings have been
secured at major wholesalers and shipments of FeraMAX(R) Powder, to over 30
wholesale distribution centres supplying pharmacies across Canada, will commence
over the next week.


"The launch of FeraMAX(R) Powder further strenghtens BioSyent Pharma's
leadership position in providing innovative iron supplement solutions for
healthcare professionals and their patients" said Rene Goehrum, President and
CEO of BioSyent. "We now have a full range of solutions and dosing options
available for all iron deficient and iron deficient anaemia patients".


For more information regarding FeraMAX(R) Powder and FeraMAX(R) 150, visit
www.feramax.com 


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada. 


At the date of this press release the Company had 13,571,195 shares issued and
outstanding. 


This press release may contain information or statements that are
forward-looking.  The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements.  Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com

Biosyent (TSXV:RX)
Historical Stock Chart
From Mar 2024 to Apr 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2023 to Apr 2024